Drugs / MBS314
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06232096 | Feb 2024 → Feb 2026 overdue | refractory plasma cell neoplasm | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBS314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06232096 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT06232096 ↗ |